Fractyl's new catheter patent runs to 2042 as the company heads toward an FDA De Novo submission, backed by its positive six-month REMAIN-1 results.
Recap by typeshit. Full story at Quiver Quantitative.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
FT Weekend sits down with Lotte Bjerre Knudsen, a key scientist behind GLP-1 drugs, who has a message for food makers.
A shared study finding says people on GLP-1 drugs cut their drink spending by about 30 percent when they go out.
Loading…